Know Cancer

or
forgot password

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent


N/A
50 Years
N/A
Open (Enrolling)
Male
GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients

Thank you

Trial Information

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent


MC MD


Inclusion Criteria:



- Korean prostate cancer over 50 years old with pathological confirmation

- Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination
within 6 months since starting.

- Patients measured bone density level before starting to receive hormone therapies
above.

Exclusion Criteria:

- Patients who are treated other anti-osteoporosis drugs and who are treated
bisphosphate due to BMD T score below -3.0.

- Patients who are hard to be analysed by attach to other bone disease.

- Patients who are hard to be analysed by limitation of chart record according to
investigators'discretion.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

comparison of bone density before and after hormone therapy

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Joon Woo Bahn

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca Korea

Authority:

Korea: Food and Drug Administration

Study ID:

NIS-OKR-CAS-2010/1

NCT ID:

NCT01303692

Start Date:

April 2011

Completion Date:

January 2014

Related Keywords:

  • GnRH Agonist Alone vs. GnRH Agonist Plus Anti-androgen Combination Treated Prostate Cancer Patients
  • bone mineral loss
  • prostate cancer
  • GnRH agonist alone vs. GnRH agonist plus anti-androgen combination
  • Prostatic Neoplasms

Name

Location